ReviewEuropean geriatric medicine2023
Therapeutic dilemma's: antipsychotics use for neuropsychiatric symptoms of dementia, delirium and insomnia and risk of falling in older adults, a clinical review.
Review in European geriatric medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Exploring Antipsychotic Use for Delirium Management in Adults in Hospital, Sub-Acute Rehabilitation and Aged Care Settings: A Systematic Literature Review.Drugs & aging · 2024Pooled it
- A Narrative Review of Medication Optimisation in Older Adults with Polypharmacy: From Structured Medication Review to AI-Enabled Medication Safety.Healthcare (Basel, Switzerland) · 2026Review
- From Sensory Deprivation to Psychosis: Environmental Mechanisms of Delirium in Dementia-An Eight-Year Retrospective Longitudinal Case Report and Narrative Review.Healthcare (Basel, Switzerland) · 2026Article
- Prevalence of delirium in German nursing homes: A cross-sectional study.BMC geriatrics · 2026Article
- The combined association of STOPPFall medication use and orthostatic blood pressure abnormalities with future falls and fractures in community-dwelling older people.European geriatric medicine · 2026Article
- Article
- Definition and Test-Retest Reliability of a Monitoring Method Integrating Accelerometric Actigraphy and Bluetooth Indoor Location Tracking Applied in a Long-Term Residential Unit for Persons With Dementia: Longitudinal Observational Study.JMIR mHealth and uHealth · 2026Observational
- Trends in use of antipsychotics in Germany 2014-2024: a nationwide population-based study.BMC psychiatry · 2026Article
- Venlafaxine and Delirium: Understanding the Association.Current neuropharmacology · 2026Review
- Review
- Behavioral symptoms of dementia and psychotropic use during the COVID-19 pandemic.Frontiers in epidemiology · 2026Article
- A retrospective risk factor analysis in psychiatric inpatients with COVID-19 from 2020 to 2023 at a neuropsychiatric hospital in Tokyo.PCN reports : psychiatry and clinical neurosciences · 2025Article
- Prevalence and association of fall-risk-increasing drugs (FRIDs) with fall-related head and non-head injuries in older adults: a retrospective database study.Scientific reports · 2025Observational
- Comparing the Metabolic, Systemic, and Neuropsychiatric Impacts of Olanzapine and Clozapine in Patients with Schizophrenia.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Mortality Risk of Colistin vs. Non-Colistin Use in Cancer Patients with Multidrug-Resistant Gram-Negative Bacterial Infections: Stratified by Resistance Profile and Concomitant Medications.Medicina (Kaunas, Lithuania) · 2025Article
- Efficacy of donepezil combined with rehabilitation training in the treatment of Alzheimer's disease.Pakistan journal of medical sciences · 2025Article
- Use and Discontinuation Rates of Long-Acting Injectable Antipsychotics Between Race/Ethnicity in Older Adults Using Medicaid Databases.Journal of the American Geriatrics Society · 2025Article
- Comprehensive Machine Learning-Based Prediction Model for Delirium Risk in Older Patients with Dementia: Risk Factors Identification.Clinical interventions in aging · 2025Article
- Falls in Persons with Cognitive Impairment-Incidence and Characteristics of the Fallers.Geriatrics (Basel, Switzerland) · 2024Article
- Adopting STOPP/START Criteria Version 3 in Clinical Practice: A Q&A Guide for Healthcare Professionals.Drug safety · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeBecause of the common and increasing use of antipsychotics in older adults, we aim to summarize the current knowledge on the causes of antipsychotic-related risk of falls in older adults. We also aim to provide information on the use of antipsychotics in dementia, delirium and insomnia, their adverse effects and an overview of the pharmacokinetic and pharmacodynamic mechanisms associated with antipsychotic use and falls. Finally, we aim to provide information to clinicians for weighing the benefits and harms of (de)prescribing.
methodsA literature search was executed in CINAHL, PubMed and Scopus in March 2022 to identify studies focusing on fall-related adverse effects of the antipsychotic use in older adults. We focused on the antipsychotic use for neuropsychiatric symptoms of dementia, insomnia, and delirium.
resultsAntipsychotics increase the risk of falls through anticholinergic, orthostatic and extrapyramidal effects, sedation, and adverse effects on cardio- and cerebrovascular system. Practical resources and algorithms are available that guide and assist clinicians in deprescribing antipsychotics without current indication.
conclusionsDeprescribing of antipsychotics should be considered and encouraged in older people at risk of falling, especially when prescribed for neuropsychiatric symptoms of dementia, delirium or insomnia. If antipsychotics are still needed, we recommend that the benefits and harms of antipsychotic use should be reassessed within two to four weeks of prescription. If the use of antipsychotic causes more harm than benefit, the deprescribing process should be started.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.